EMEA-001397-PIP03-14-M03

Key facts

Invented name
Imbruvica
Active substance
Ibrutinib
Therapeutic area
Oncology
Decision number
P/0398/2017
PIP number
EMEA-001397-PIP03-14-M03
Pharmaceutical form(s)
  • Capsule, hard
  • Oral suspension
Condition(s) / indication(s)
Treatment of mature B-cell neoplasm
Route(s) of administration
Oral use
Contact for public enquiries
Janssen-Cilag International N.V.
Tel.: +49 2638 9479218
E-mail: sglawe@its.jnj.com
 
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating